Adverse events not up with six months of DAPT

Adverse events not up with six months of DAPT

(HealthDay)—For patients receiving an everolimus-eluting stent implantation, six months of dual antiplatelet therapy (DAPT) does not increase composite events compared with 12 months of DAPT, according to a study published online May 17 in JACC: Cardiovascular Interventions to coincide with EuroPCR 2016, held from May 17 to 20 in Paris.

Sung-Jin Hong, M.D., from Inje University in Seoul, South Korea, and colleagues randomized 1,400 patients (implanted mean total stent length >45 mm) receiving an everolimus-eluting stent implantation to receive six-month (699 patients) or 12-month (701 patients) DAPT.

The researchers found that the primary end point (composite of , , stroke, or thrombolysis in myocardial infarction [TIMI] major bleeding at one year) occurred in 2.2 and 2.1 percent of patients in the six- and 12-month DAPT groups, respectively (hazard ratio, 1.07; P = 0.854). Definite or possible stent thrombosis occurred in 0.3 percent of patients in both the six- and 12-month groups (hazard ratio, 1.00; P = 0.999). No significant differences were seen between the groups in the primary end point among 686 patients with and 506 patients with diabetes mellitus.

"Compared to 12-month DAPT, six-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI at one year in the patients who received an everolimus-eluting stent implantation," the authors write.

The study was partially funded by Abbott Vascular.

More information: Full Text (subscription or payment may be required)
More Information

Copyright © 2016 HealthDay. All rights reserved.

Citation: Adverse events not up with six months of DAPT (2016, May 19) retrieved 18 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Six-month dual antiplatelet tx noninferior to 24-month DAPT


Feedback to editors